GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
USA Today14d
No, Hurricane Milton didn't 'destroy' Disney World | Fact check
An Oct. 10 Facebook post (direct link, archive link) shows a video of Walt Disney World in Orlando that includes scenes of severe flooding and storm damage. “BREAKING: Disney World Destroyed By ...
Mena FN14d
Clover Announces Positive Clinical Data For RSV Vaccine Candidate SCB-1019 Compared Head-To-Head Versus GSK's AREXVY
"We are pleased to announce positive head-to-head clinical data for our non-adjuvanted SCB-1019 RSV vaccine candidate compared to AS01E-adjuvanted AREXVY ... of historical fact nor guarantees ...
Vietnam Investment Reviev14d
I-Mab to Participate at the Truist Securities BioPharma Symposium
I-Mab, a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will ...
Vietnam Investment Reviev14d
Synechron Acquires Cloobees, a global Salesforce summit partner
Synechron, Inc., a leading global digital transformation consulting firm, announced today that it has acquired Cloobees, an award winning, top-tier Salesforce implementation partner. Cloobees will add ...
MarketWatch14d
GSK Net Profit Expected to Rise, Turnover to Fall -- Earnings Preview
WHAT TO WATCH --VACCINES: Investors' concerns linger over sales expectations for the company's respiratory syncytial virus vaccine Arexvy and its best-selling shingles vaccine Shingrix for the ...
Eagle-Tribune14d
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
The 2023 approval of the world's first RSV vaccines in the US and Europe, GSK’s AREXVY and Pfizer’s ABRYSVO, was a significant milestone in addressing the grave unmet medical needs associated ...
pulmonologyadvisor14d
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...
Associated Press16d
FACT FOCUS: Trump repeated election lies in his interview with Joe Rogan. Here are the facts
WHAT TRUMP SAID: “I won by like — they say I lost by like — I didn’t lose.” THE FACTS: Trump did lose in 2020 to Democrat Joe Biden. Trump’s claims that fraud cost him the race were investigated ...
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
Pharmabiz17d
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical ...